MoneyWorks4Me

GlaxoSmithKline submits revised disclosure

22 Mar 2017 Evaluate

The Exchange has now received the revised disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1) (a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for GlaxoSmithKline.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1145.25
Cipla 1359.75
Lupin 2047.20
Zydus Lifesciences 1105.00
View more..